Randomized, Open-label, Multi-center and Phase 3 Clinical Trial to Compare the Efficacy and Safety of 'Green Cross CELL Immuncell-LC Group' and 'Non-treatment Group' in Patient Undergone Curative Resection(PEIT, RFA or Operation) for Hepatocellular Carcinoma in Korea
Latest Information Update: 26 Jul 2024
At a glance
- Drugs GCC 4002 (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- Sponsors GC Cell
Most Recent Events
- 26 Jul 2024 New trial record